New CAR t therapy trial hopes to tackle tough leukemia in kids
NCT ID NCT06709469
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This early-stage trial is testing a type of immunotherapy called CAR T cells in children, adolescents, and young adults with acute lymphoblastic leukemia that has come back or not responded to standard treatments. The study will use two different CAR T products based on the patient's leukemia type. The main goal is to see if the treatment is safe and feasible, with only 10 participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario La Paz
RECRUITINGMadrid, Madrid, 28046, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR T cells (CD19/CD22 and NKG2D)
What this could lead to
If successful, this could offer a new treatment option for young patients with leukemia that has not responded to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 10 participants, so it is primarily testing safety. The treatment may not work, and there are risks of serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.